NASDAQ | ETF
The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies.
Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics.
The fund is non-diversified.
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| AMGN | Amgen Inc | Healthcare | Drug Manufacturers - General | 5.28% |
| GILD | Gilead Sciences Inc | Healthcare | Drug Manufacturers - General | 4.98% |
| VRTX | Vertex Pharmaceuticals Inc | Healthcare | Biotechnology | 4.87% |
| REGN | Regeneron Pharmaceuticals Inc | Healthcare | Biotechnology | 4.32% |
| ALNY | Alnylam Pharmaceuticals Inc | Healthcare | Biotechnology | 3.08% |
| AZN | AstraZeneca PLC ADR | Healthcare | Drug Manufacturers - General | 2.57% |
| INSM | Insmed Inc | Healthcare | Biotechnology | 2.30% |
| ARGX | argenx NV ADR | Healthcare | Biotechnology | 1.50% |
| BIIB | Biogen Inc | Healthcare | Drug Manufacturers - General | 1.42% |
| UTHR | United Therapeutics Corporation | Healthcare | Drug Manufacturers - Specialty & Generic | 1.18% |
| ITCI | Intracellular Th | Healthcare | Drug Manufacturers - Specialty & Generic | 1.17% |
| INCY | Incyte Corporation | Healthcare | Biotechnology | 1.10% |
| ILMN | Illumina Inc | Healthcare | Diagnostics & Research | 1.06% |
| KRTX | Karuna Therapeutics Inc | Healthcare | Biotechnology | 0.92% |
| RPRX | Royalty Pharma Plc | Healthcare | Biotechnology | 0.92% |
| MEDP | Medpace Holdings Inc | Healthcare | Diagnostics & Research | 0.91% |
| NBIX | Neurocrine Biosciences Inc | Healthcare | Drug Manufacturers - Specialty & Generic | 0.80% |
| RVMD | Revolution Medicines Inc | Healthcare | Biotechnology | 0.77% |
| ROIV | Roivant Sciences Ltd | Healthcare | Biotechnology | 0.76% |
| BBIO | BridgeBio Pharma Inc | Healthcare | Biotechnology | 0.73% |